Stock Market Today (3 November 2026): GSK Pharma, HG Infra, Dalmia Sugar in Focus

Corporate earnings and expansion plans remained the centre of attention in the Indian stock market on 3 November 2026. GSK India reported strong Q2 growth, Dalmia Bharat Sugar delivered a sharp jump in profit, and HG Infra continued to show a large order-book position despite mixed profit signals in the evening updates. Gujarat Fluorochemicals announced a ₹6,000 crore investment plan, while Marico outlined an ambitious ₹20,000 crore revenue target for FY30.

Today's Key Market Highlights

GSK India Q2 Profit Jumps 31%, Revenue Rises 21%

GSK India delivered one of the stronger pharmaceutical updates of the day. Q2 profit increased 31% year on year, while revenue rose 21%. EBITDA also improved, with the company's Q2 EBITDA reported at around ₹400 crore, up 18%.

The combination of double-digit revenue growth and stronger profitability gives the company a constructive earnings profile. Investors will now be watching whether the momentum can continue across its core brands and whether operating margins remain resilient as costs evolve.

Dalmia Bharat Sugar Q2 PAT Surges 203%

Dalmia Bharat Sugar delivered one of the sharpest profit-growth numbers in the day's earnings updates, with Q2 profit after tax jumping 203%. The company also reported higher revenue, keeping the sugar business firmly on the earnings radar.

A three-digit increase in profit can look striking, but sugar companies are highly sensitive to realisations, cane costs, production volumes and the broader commodity cycle. Investors should therefore focus on the underlying margin improvement and whether the performance can be sustained through the remainder of the financial year.

HG Infra: ₹13,685 Crore Order Book Provides Visibility

HG Infra Engineering reported a strong ₹13,685 crore order book, highlighting the company's sizeable execution pipeline across its infrastructure business.

The order book remains one of the key reasons to track the stock. A large pipeline can provide revenue visibility, but conversion into profitable revenue depends on execution timelines, project costs, working capital and the pace of new order inflows.

One caution: the evening feed carried conflicting updates on HG Infra's Q2 profit, including both a 52% rise and a 52% decline. Since the supplied feed does not resolve the discrepancy, the order-book figure is the more reliable point to highlight here rather than assigning a definitive profit-growth number.

Gujarat Fluorochemicals Plans ₹6,000 Crore Investment

Gujarat Fluorochemicals announced plans to invest approximately ₹6,000 crore, putting the company among the day's notable capital-expenditure stories.

Large investment programmes can strengthen long-term capacity and open new growth opportunities, but they also increase the importance of capital allocation, project execution and eventual returns on invested capital. Investors will be looking for more clarity on the projects, timelines and funding structure as the plan progresses.

Marico Targets ₹20,000 Crore by FY30

Marico has set an ambitious target of reaching ₹20,000 crore in scale by FY30. The target puts renewed attention on the company's medium-term growth strategy and its ability to expand across core consumer categories.

For investors, the important question is not simply whether the target is achievable, but how much of the growth will come from volume expansion, pricing, premiumisation and new categories. Margin quality and cash generation will also matter as the company pursues the target.

Granules India Plans Five US Product Launches

Granules India plans to launch five products in the US market. The move adds another growth angle to the company's international business and keeps its product pipeline in focus.

US launches can be meaningful for Indian pharmaceutical companies when supported by attractive market opportunities and sustainable margins. Investors will therefore track approval timelines, launch execution and the potential contribution of these products to future revenue.

Trident Reports Q2 PBT of ₹232 Crore

Trident reported Q2 profit before tax of ₹232 crore. The result adds to the company's ongoing earnings narrative across its textiles and paper-related businesses.

Investors will be watching demand conditions, input costs and the company's ability to convert revenue growth into stronger operating profitability in the coming quarters.

Lux Industries Q2 Revenue Falls YoY

Lux Industries reported a year-on-year decline in Q2 revenue. The weaker top line puts the focus on demand conditions, product mix and the company's ability to protect profitability in a competitive innerwear market.

Glaxo Pharma Q2 EBITDA Rises 18%

Glaxo Pharma reported Q2 EBITDA of approximately ₹400 crore, up 18%. The improvement points to healthy operating performance and keeps the company among the notable pharmaceutical names in today's earnings updates.

The company also appointed a compliance head, adding a corporate-governance update alongside the quarterly results.

Chambal Fertilisers Reports H1 Revenue of ₹12,026 Crore

Chambal Fertilisers reported H1 revenue of ₹12,026 crore. The company remains an important name in the fertiliser sector, where investors closely track volumes, raw-material costs, government policy and subsidy-related developments.

Max India Targets Breakeven by FY28

Max India has set a target of reaching breakeven by FY28. The timeline provides investors with a medium-term milestone against which the company's operating progress can be measured.

For a business targeting breakeven, revenue growth alone is not enough. Cost discipline, operating leverage and cash requirements will be important indicators as the company moves toward the target.

Jefferies Sees Up to 47% Upside in Banks

Jefferies sees potential upside of up to 47% in select banking stocks. The brokerage view adds another layer to the banking-sector narrative, although individual stock selection remains critical.

Investors should distinguish between a broad sector call and the fundamentals of individual lenders, particularly around credit growth, asset quality, deposit costs, net interest margins and valuation.

Other Important Corporate Updates

• Granules India: Plans five product launches in the US market.
• Marico: Targets ₹20,000 crore by FY30.
• Trident: Reports Q2 profit before tax of ₹232 crore.
• GSK India: Q2 profit rises 31% and revenue increases 21%.
• Dalmia Bharat Sugar: Q2 PAT jumps 203.
• HG Infra: Order book reaches ₹13,685 crore.
• Gujarat Fluorochemicals: Announces a ₹6,000 crore investment plan.
• Lux Industries: Q2 revenue declines year on year.
• Max India: Targets breakeven by FY28.
• Dalmia Bharat Sugar: DBSIL approves the proposed Hippostores demerger.

Market Outlook

The earnings season continues to produce a wide spread in performance. GSK India and Dalmia Bharat Sugar delivered strong headline numbers, while HG Infra's large order book provides visibility despite the conflicting profit updates in the supplied feed.

Beyond quarterly results, the bigger themes today were capital expenditure and medium-term growth targets. Gujarat Fluorochemicals' ₹6,000 crore investment plan and Marico's ₹20,000 crore FY30 target are developments that investors will assess over a much longer horizon than a single quarter.

The pharmaceutical sector also remains active, with Granules India planning five US launches and GSK reporting strong growth. Meanwhile, banking stocks could stay in focus after Jefferies highlighted potential upside of up to 47% in selected names.

For the next sessions, investors should separate headline growth from sustainable earnings. Revenue growth, margins, cash generation, order-book execution and return on capital will be the more useful indicators when assessing whether today's positive announcements can translate into lasting value.

Stocks to Watch